Development of Novel Diclofenac Analogs Designed to Avoid Metabolic Activation and Hepatocyte Toxicity

[Image: see text] Diclofenac (DCF) is widely used as a nonsteroidal anti-inflammatory drug; however, it is associated with severe liver injury. This adverse reaction is thought to be related to the reactive quinone imine (QI) and acyl glucuronide (AG) metabolites of DCF, but it remains controversial...

Descripción completa

Detalles Bibliográficos
Autores principales: Tateishi, Yasuhiro, Ohe, Tomoyuki, Ogawa, Mai, Takahashi, Kyoko, Nakamura, Shigeo, Mashino, Tadahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758955/
https://www.ncbi.nlm.nih.gov/pubmed/33376898
http://dx.doi.org/10.1021/acsomega.0c04942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7758955/
https://www.ncbi.nlm.nih.gov/pubmed/33376898
http://dx.doi.org/10.1021/acsomega.0c04942

Ejemplares similares